Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Johnson & Johnson ( (JNJ) ) has issued an announcement.
On April 14, 2026, Johnson & Johnson reported first-quarter 2026 sales of $24.1 billion, up 9.9% year on year, with operational growth of 6.4% and adjusted EPS of $2.70, while GAAP EPS fell 52.9% to $2.14 due to special items. Innovative Medicine and MedTech both delivered solid operational gains, supported by key products such as DARZALEX, TREMFYA and electrophysiology devices, prompting the company to raise its 2026 sales and earnings outlook and underscoring its strategy to accelerate growth and enhance long-term shareholder value.
Also on April 14, 2026, the board approved a 3.1% increase in the quarterly dividend from $1.30 to $1.34 per share, lifting the indicated annual payout to $5.36 and extending the firm’s record to 64 consecutive years of dividend increases. The higher dividend, payable on June 9, 2026 to shareholders of record as of May 26, 2026, reinforces Johnson & Johnson’s image as an income-oriented blue chip and signals continued confidence in its cash generation and financial resilience.
The most recent analyst rating on (JNJ) stock is a Hold with a $234.00 price target. To see the full list of analyst forecasts on Johnson & Johnson stock, see the JNJ Stock Forecast page.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
The score is driven primarily by strong, durable cash generation and solid operating performance, reinforced by constructive 2026 guidance and portfolio/pipeline momentum. The rating is tempered by stretched technical conditions, moderate-to-premium valuation, and ongoing headwinds (tariffs, litigation/one-time charges, and residual biosimilar/competitive pressures).
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
Johnson & Johnson, headquartered in New Brunswick, N.J., is a global healthcare company operating across Innovative Medicine and MedTech, with a portfolio spanning oncology, immunology, neuroscience, cardiovascular devices and orthopaedics. The group focuses on high-growth, innovation-led therapies and technologies, targeting both U.S. and international markets and positioning itself for sustained double-digit growth later in the decade.
Average Trading Volume: 8,624,884
Technical Sentiment Signal: Buy
Current Market Cap: $574.4B
For an in-depth examination of JNJ stock, go to TipRanks’ Overview page.